70 FR 65 pg. 17319 - New Animal Drugs; Change of Sponsor
Type: RULEVolume: 70Number: 65Page: 17319
FR document: [FR Doc. 05-6721 Filed 4-5-05; 8:45 am]
Agency: Health and Human Services Department
Sub Agency: Food and Drug Administration
Official PDF Version: PDF Version
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
21 CFR Parts 510 and 520
New Animal Drugs; Change of Sponsor
AGENCY:
Food and Drug Administration, HHS.
ACTION:
Final rule.
SUMMARY:
The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect a change of sponsor for a new animal drug application (NADA) from Akzo Nobel Surface Chemistry AB (Azko Nobel) to Virbac AH, Inc.
DATES:
This rule is effective April 6, 2005.
FOR FURTHER INFORMATION CONTACT:
David R. Newkirk, Center for Veterinary Medicine (HFV-100), Food and Drug Administration,7500 Standish Pl., Rockville, MD 20855, 301-827-6967, e-mail: david.newkirk@fda.gov .
SUPPLEMENTARY INFORMATION:
Akzo Nobel, Box 851, S-44485 Stenungsund, Sweden, has informed FDA that it has transferred ownership of, and all rights and interest in, NADA 10-886 for Purina Liquid Wormer to Virbac AH, Inc., 3200 Meacham Blvd., Ft. Worth, TX 76137.
Following this change of sponsorship, Akzo Nobel is no longer the sponsor of an approved application. Accordingly, 21 CFR 510.600(c) is being amended to remove the entries for Akzo Nobel.
Purina Liquid Wormer (NADA 10-886) is labeled for use in chickens, turkeys, and swine. The drug was the subject of a National Academy of Sciences/National Research Council evaluation of effectiveness under FDA's drug efficacy study implementation (DESI) program (DESI 10-005V). The findings of the evaluation were published in the Federal Register of February 14, 1969 (34 FR 2213). A separate entry in part 520 (21 CFR part 520) (§ 520.1807) was created (64 FR 23017, April 29, 1999) to accommodate oral piperazine products approved for use in chickens, turkeys, and swine consistent with DESI findings and human food safety requirements (DESI finalization). However to date, NADA 10-886 has not been DESI finalized. Accordingly, § 520.1807 will not be amended to reflect the approval of NADA 10-886 until the current sponsor of that NADA submits a supplemental NADA adequate for DESI finalization.
In addition, § 520.1806 has been found to inaccurately list Akzo Nobel as the sponsor of an oral piperazine product approved for use indogs. This error occurred during the codification of a previous change ofsponsor for NADA 10-886 (59 FR 28763, June 3, 1994). Accordingly,the agency is amending the regulations in § 520.1806 to removeAkzo Nobel's drug labeler code and to reflect the current format.
This rule does not meet the definition of "rule" in 5 U.S.C.804(3)(A) because it is a rule of "particular applicability."Therefore, it is not subject to the congressional review requirements in 5U.S.C. 801-808.
List of Subjects
21 CFR Part 510
Administrative practice and procedure, Animal drugs, Labeling, Reportingand recordkeeping requirements.
21 CFR Part 520
Animal drugs.
Therefore, under the Federal Food, Drug and Cosmetic Act and underauthority delegated to the Commissioner of Food and Drugs and redelegatedto the Center for Veterinary Medicine, 21 CFR parts 510 and 520 are amendedas follows:
PART 510-NEW ANIMAL DRUGS
1. The authority citation for 21 CFR part 510 continues to read asfollows:
Authority:
21 U.S.C. 321, 331, 351, 352, 353, 360b, 371,379e.
§ 510.600 [Amended]
2. Section 510.600 is amended in the table in paragraph (c)(1) byremoving the entry for "Akzo Nobel Surface Chemistry AB" and inthe table in paragraph (c)(2) by removing the entry for "063765".
PART 520-ORAL DOSAGE FORM NEW ANIMAL DRUGS
3. The authority citation for 21 CFR part 520 continues to read asfollows:
Authority:
21 U.S.C. 360b.
4. Section 520.1806 is revised to read as follows:
§ 520.1806 Piperazinesuspension.
(a) Specifications . Each milliliter of suspension containspiperazine monohydrochloride equivalent to 33.5 milligrams (mg) piperazinebase.
(b) Sponsor . See No. 017135 in § 510.600(c) ofthis chapter.
(c) Special considerations . See § 500.25(c) ofthis chapter.
(d) Conditions of use in dogs -(1) Indications for use . For the removal of roundworms ( Toxocara canis and Toxascaris leonina ).
(2) Dosage . Administer 20 to 30 mg piperazine base perpound body weight as a single dose.
(3) Limitations . Administer by mixing into the animal'sration to be consumed at one feeding. For animals in heavily contaminatedareas, reworm at monthly intervals. Not for use in unweaned pups oranimals less than 3 weeks of age.
Dated: December 10, 2004.
Steven D. Vaughn,
Director, Office of New Animal Drug Evaluation, Center forVeterinary Medicine.
[FR Doc. 05-6721 Filed 4-5-05; 8:45 am]
BILLING CODE 4160-01-S